Differences in downstream activation of mGluR1 through glutamate between hormone sensitive versus hormone refractory tumors may explain the difference in prognostic value of mGluR1 in hormone receptor positive versus the important hormone receptor negative breast cancer subgroup30–32. The gene discussed is NR4A1; the disease is breast carcinoma.